Compare MCHB & IDYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MCHB | IDYA |
|---|---|---|
| Founded | 1905 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.2B | 2.9B |
| IPO Year | N/A | 2019 |
| Metric | MCHB | IDYA |
|---|---|---|
| Price | $15.05 | $31.81 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 14 |
| Target Price | $14.50 | ★ $49.67 |
| AVG Volume (30 Days) | 414.8K | ★ 889.0K |
| Earning Date | 01-30-2026 | 02-13-2026 |
| Dividend Yield | ★ 2.73% | N/A |
| EPS Growth | ★ 774.83 | N/A |
| EPS | ★ 1.20 | N/A |
| Revenue | ★ $642,660,000.00 | $214,834,000.00 |
| Revenue This Year | $80.74 | $2,688.43 |
| Revenue Next Year | $29.94 | N/A |
| P/E Ratio | $12.89 | ★ N/A |
| Revenue Growth | 68.43 | ★ 5377.66 |
| 52 Week Low | $6.46 | $13.45 |
| 52 Week High | $15.97 | $39.28 |
| Indicator | MCHB | IDYA |
|---|---|---|
| Relative Strength Index (RSI) | 51.12 | 37.80 |
| Support Level | $14.42 | $31.62 |
| Resistance Level | $15.97 | $34.66 |
| Average True Range (ATR) | 0.61 | 1.45 |
| MACD | 0.03 | -0.37 |
| Stochastic Oscillator | 39.53 | 0.95 |
Mechanics Bancorp is an independent, full-service community bank. It provides personal banking, business banking, trust and estate, brokerage and wealth management services. Mechanics' retail banking products include personal checking, savings and loan products (including credit card, home equity, home mortgage and secured/unsecured loans), online banking and wealth management services (including trust and estate, investment management and financial planning services). Mechanics' banking products and services for businesses include business checking and savings accounts, business debit cards, online banking, cash management services, wealth management services, business credit cards, commercial real estate loans, equipment leasing and loans guaranteed by the Small Business Administration.
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275/GSK959 (Werner Helicase), IDE161 (PARG), and IDE705/GSK101 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.